Literature DB >> 29223583

The global burden of tuberculosis: results from the Global Burden of Disease Study 2015.

.   

Abstract

BACKGROUND: An understanding of the trends in tuberculosis incidence, prevalence, and mortality is crucial to tracking of the success of tuberculosis control programmes and identification of remaining challenges. We assessed trends in the fatal and non-fatal burden of tuberculosis over the past 25 years for 195 countries and territories.
METHODS: We analysed 10 691 site-years of vital registration data, 768 site-years of verbal autopsy data, and 361 site-years of mortality surveillance data using the Cause of Death Ensemble model to estimate tuberculosis mortality rates. We analysed all available age-specific and sex-specific data sources, including annual case notifications, prevalence surveys, and estimated cause-specific mortality, to generate internally consistent estimates of incidence, prevalence, and mortality using DisMod-MR 2.1, a Bayesian meta-regression tool. We assessed how observed tuberculosis incidence, prevalence, and mortality differed from expected trends as predicted by the Socio-demographic Index (SDI), a composite indicator based on income per capita, average years of schooling, and total fertility rate. We also estimated tuberculosis mortality and disability-adjusted life-years attributable to the independent effects of risk factors including smoking, alcohol use, and diabetes.
FINDINGS: Globally, in 2015, the number of tuberculosis incident cases (including new and relapse cases) was 10·2 million (95% uncertainty interval 9·2 million to 11·5 million), the number of prevalent cases was 10·1 million (9·2 million to 11·1 million), and the number of deaths was 1·3 million (1·1 million to 1·6 million). Among individuals who were HIV negative, the number of incident cases was 8·8 million (8·0 million to 9·9 million), the number of prevalent cases was 8·9 million (8·1 million to 9·7 million), and the number of deaths was 1·1 million (0·9 million to 1·4 million). Annualised rates of change from 2005 to 2015 showed a faster decline in mortality (-4·1% [-5·0 to -3·4]) than in incidence (-1·6% [-1·9 to -1·2]) and prevalence (-0·7% [-1·0 to -0·5]) among HIV-negative individuals. The SDI was inversely associated with HIV-negative mortality rates but did not show a clear gradient for incidence and prevalence. Most of Asia, eastern Europe, and sub-Saharan Africa had higher rates of HIV-negative tuberculosis burden than expected given their SDI. Alcohol use accounted for 11·4% (9·3-13·0) of global tuberculosis deaths among HIV-negative individuals in 2015, diabetes accounted for 10·6% (6·8-14·8), and smoking accounted for 7·8% (3·8-12·0).
INTERPRETATION: Despite a concerted global effort to reduce the burden of tuberculosis, it still causes a large disease burden globally. Strengthening of health systems for early detection of tuberculosis and improvement of the quality of tuberculosis care, including prompt and accurate diagnosis, early initiation of treatment, and regular follow-up, are priorities. Countries with higher than expected tuberculosis rates for their level of sociodemographic development should investigate the reasons for lagging behind and take remedial action. Efforts to prevent smoking, alcohol use, and diabetes could also substantially reduce the burden of tuberculosis. FUNDING: Bill & Melinda Gates Foundation.
Copyright © 2018 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Mesh:

Year:  2017        PMID: 29223583      PMCID: PMC5831985          DOI: 10.1016/S1473-3099(17)30703-X

Source DB:  PubMed          Journal:  Lancet Infect Dis        ISSN: 1473-3099            Impact factor:   71.421


  57 in total

1.  Design options for sample-based mortality surveillance.

Authors:  Stephen Begg; Chalapati Rao; Alan D Lopez
Journal:  Int J Epidemiol       Date:  2005-05-23       Impact factor: 7.196

2.  Tuberculosis 2000-2010: control, but not elimination.

Authors:  C Dye
Journal:  Int J Tuberc Lung Dis       Date:  2000-12       Impact factor: 2.373

3.  Tuberculosis and substance abuse in the United States, 1997-2006.

Authors:  John E Oeltmann; J Steve Kammerer; Eric S Pevzner; Patrick K Moonan
Journal:  Arch Intern Med       Date:  2009-01-26

Review 4.  Sexual inequality in tuberculosis.

Authors:  Olivier Neyrolles; Lluis Quintana-Murci
Journal:  PLoS Med       Date:  2009-12-22       Impact factor: 11.069

5.  Evidence for waning of latency in a cohort study of tuberculosis.

Authors:  Harald G Wiker; Tehmina Mustafa; Gunnar A Bjune; Morten Harboe
Journal:  BMC Infect Dis       Date:  2010-02-23       Impact factor: 3.090

Review 6.  The relationship between malnutrition and tuberculosis: evidence from studies in humans and experimental animals.

Authors:  J P Cegielski; D N McMurray
Journal:  Int J Tuberc Lung Dis       Date:  2004-03       Impact factor: 2.373

7.  Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015.

Authors: 
Journal:  Lancet       Date:  2016-10-08       Impact factor: 79.321

8.  Risk factors for tuberculosis.

Authors:  Padmanesan Narasimhan; James Wood; Chandini Raina Macintyre; Dilip Mathai
Journal:  Pulm Med       Date:  2013-02-12

Review 9.  TB as a cause of hospitalization and in-hospital mortality among people living with HIV worldwide: a systematic review and meta-analysis.

Authors:  Nathan Ford; Alberto Matteelli; Zara Shubber; Sabine Hermans; Graeme Meintjes; Beatriz Grinsztejn; Greer Waldrop; Katharina Kranzer; Meg Doherty; Haileyesus Getahun
Journal:  J Int AIDS Soc       Date:  2016-01-12       Impact factor: 5.396

Review 10.  The WHO's new End TB Strategy in the post-2015 era of the Sustainable Development Goals.

Authors:  Knut Lönnroth; Mario Raviglione
Journal:  Trans R Soc Trop Med Hyg       Date:  2016-03       Impact factor: 2.184

View more
  88 in total

Review 1.  Stress Hyperglycemia in Patients with Tuberculosis Disease: Epidemiology and Clinical Implications.

Authors:  Matthew J Magee; Argita D Salindri; Nang Thu Thu Kyaw; Sara C Auld; J Sonya Haw; Guillermo E Umpierrez
Journal:  Curr Diab Rep       Date:  2018-08-09       Impact factor: 4.810

2.  The impact of alcohol use on tuberculosis treatment outcomes: a systematic review and meta-analysis.

Authors:  E J Ragan; M B Kleinman; B Sweigart; N Gnatienko; C D Parry; C R Horsburgh; M P LaValley; B Myers; K R Jacobson
Journal:  Int J Tuberc Lung Dis       Date:  2020-01-01       Impact factor: 2.373

3.  Macrophage-targeted drugamers with enzyme-cleavable linkers deliver high intracellular drug dosing and sustained drug pharmacokinetics against alveolar pulmonary infections.

Authors:  Fang-Yi Su; Selvi Srinivasan; Brian Lee; Jasmin Chen; Anthony J Convertine; Timothy Eoin West; Daniel M Ratner; Shawn J Skerrett; Patrick S Stayton
Journal:  J Control Release       Date:  2018-08-09       Impact factor: 9.776

4.  Household fuel use and pulmonary tuberculosis in western Nepal: A case-control study.

Authors:  Michael N Bates; Karl Pope; Tula Ram Sijali; Amod K Pokhrel; Ajay Pillarisetti; Nicholas L Lam; Sharat C Verma
Journal:  Environ Res       Date:  2018-09-27       Impact factor: 6.498

5.  Overweight, Obesity, and Older Age Favor Latent Tuberculosis Infection among Household Contacts in Low Tuberculosis-Incidence Settings within Panama.

Authors:  Idalina Cubilla-Batista; Nadia Ruiz; Dilcia Sambrano; Juan Castillo; Markela O de Quinzada; Begoña Gasteluiturri; Amador Goodridge
Journal:  Am J Trop Med Hyg       Date:  2019-05       Impact factor: 2.345

6.  Yield, Efficiency, and Costs of Mass Screening Algorithms for Tuberculosis in Brazilian Prisons.

Authors:  Andrea da Silva Santos; Roberto Dias de Oliveira; Everton Ferreira Lemos; Fabiano Lima; Ted Cohen; Olivia Cords; Leonardo Martinez; Crhistinne Gonçalves; Albert Ko; Jason R Andrews; Julio Croda
Journal:  Clin Infect Dis       Date:  2021-03-01       Impact factor: 9.079

Review 7.  The present state of the tuberculosis drug development pipeline.

Authors:  M Daben J Libardo; Helena Im Boshoff; Clifton E Barry
Journal:  Curr Opin Pharmacol       Date:  2018-08-23       Impact factor: 5.547

8.  Tuberculosis Relapse in the Epididymis After the Completion of Nine Months of Anti-Tuberculosis Chemotherapy in a Patient with Poorly Controlled Diabetes Mellitus.

Authors:  Chikako Ichikawa; Sho Tanaka; Masahiro Takubo; Masaru Kushimoto; Jin Ikeda; Katsuhiko Ogawa; Ichiro Tsujino; Yutaka Suzuki; Masanori Abe; Hisamitsu Ishihara; Midori Fujishiro
Journal:  Ther Clin Risk Manag       Date:  2021-05-25       Impact factor: 2.423

9.  Active case-finding policy development, implementation and scale-up in high-burden countries: A mixed-methods survey with National Tuberculosis Programme managers and document review.

Authors:  Olivia Biermann; Phuong Bich Tran; Kerri Viney; Maxine Caws; Knut Lönnroth; Kristi Sidney Annerstedt
Journal:  PLoS One       Date:  2020-10-28       Impact factor: 3.240

10.  A dual purpose for household contact investigations: preventing TB disease and improving diabetes outcomes.

Authors:  M J Magee; N R Gandhi; H Kornfeld
Journal:  Int J Tuberc Lung Dis       Date:  2018-06-01       Impact factor: 2.373

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.